Drugs / gp140 HIV Bivalent Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02935686 | Mar 2017 → Nov 2023 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gp140 HIV Bivalent Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02935686 ↗ |
| Modality | Vaccine | “gp140 HIV Bivalent Vaccine is adjuvanted protein co-formulation with a dosage strength of 80 mcg Clade C protein, 75 mcg Mosaic protein and 425 mcg aluminum (as aluminum...” NCT02935686 ↗ |